baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC WAR. CALL 12/24 IDP/ DE000HD31TG6 /

7/26/2024 9:41:25 PM	Chg.-0.2100	Bid9:55:57 PM	Ask7/26/2024	Underlying	Strike price	Expiration date	Option type
0.1800EUR	-53.85%	0.1700 Bid Size: 12,000	- Ask Size: 12,000	BIOGEN INC. DL -,000...	320.00 -	12/18/2024	Call

GlobeNewswire 6/28 “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

GlobeNewswire 6/24 TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union

GlobeNewswire 6/10 FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application f...

GlobeNewswire 6/3 Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of ...

GlobeNewswire 5/30 Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a R...

GlobeNewswire 5/22 Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...

GlobeNewswire 5/21 Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors

GlobeNewswire 5/16 Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...

GlobeNewswire 5/15 Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...

GlobeNewswire 5/2 Biogen Reports Progress on Corporate Responsibility Priorities

GlobeNewswire 4/25 Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...

TeleTrader 4/24 Biogen posts Q1 revenue of $2.3 billion

GlobeNewswire 4/23 Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...

GlobeNewswire 4/2 ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer

GlobeNewswire 3/6 New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...

GlobeNewswire 3/4 Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...

GlobeNewswire 2/23 Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...

TeleTrader 2/13 Biogen's Q4 revenue falls 6% to $2.4 billion

GlobeNewswire 2/12 Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...

TeleTrader 2/12 Earnings preview: Robinhood, Coinbase and more

GlobeNewswire 2/8 Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

GlobeNewswire 1/4 Stran & Company Appoints Ian Thomas Wall as Chief Information Officer

GlobeNewswire 12/19/2023 Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European C...

GlobeNewswire 12/15/2023 CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Fri...

GlobeNewswire 12/14/2023 ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is...

UC WAR. CALL 12/24 IDP/ DE000HD31TG6 /

If you wish to receive reply to your feedback, please provide your email address.